A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris

NCT03341910 | Completed Phase 2 Results FDA Drug

• 1 other identifier: DFD-03-CD-008
• Study Type: interventional
• Target: 155
• Locations: 1 country
• Sites: 1

Brief Summary

A study for Subjects with mild to moderate facial acne vulgaris. During the 12-week treatment period subjects randomized to DFD-03 Lotion or Vehicle Lotion will use the study drug twice daily. Subjects randomized to Tazorac Cream or Vehicle Cream will use the study drug once daily in the evening. Safety assessments will include the investigator's assessment of local cutaneous tolerance/application site reactions on the face, vital signs and adverse events.

Conditions

Acne Vulgaris

Outcome Measures

Primary Outcomes (1)

• Adverse Event Occurences in DFD-03 Lotion Versus Tazorac Cream Groups

  Frequency count of treatment emergent adverse events will be compared between DFD-03 Lotion and Tazorac Cream groups.

  Baseline to Week 12

Study Arms (4)

DFD-03 Lotion, 0.1%

EXPERIMENTAL

DFD-03 Lotion, 0.1% to be applied twice daily approximately 12 hours apart, for 1 minute and rinsed off

Drug: DFD-03 Lotion, 0.1%

Tazorac Cream, 0.1%

ACTIVE COMPARATOR

Tazorac Cream, 0.1% to be applied once in the evening and left overnight for approximately 12 hours

Drug: Tazorac Cream, 0.1%

Vehicle Lotion

PLACEBO COMPARATOR

Vehicle Lotion to be applied twice daily for 1 minute and rinsed off

Drug: DFD-03 Vehicle Lotion 0%

Vehicle Cream

PLACEBO COMPARATOR

Vehicle Cream to be applied once in the evening and left overnight for approximately 12 hours

Drug: Tazorac Vehicle Cream 0%

Interventions

DFD-03 Lotion, 0.1% DRUG

DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.

Also known as: Tazarotene Lotion, 0.1%

DFD-03 Lotion, 0.1%

Tazorac Cream, 0.1% DRUG

Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.

Also known as: Tazarotene Cream, 0.1%

Tazorac Cream, 0.1%

DFD-03 Vehicle Lotion 0% DRUG

Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.

Also known as: Vehicle Lotion 0%

Vehicle Lotion

Tazorac Vehicle Cream 0% DRUG

Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.

Also known as: Vehicle Cream 0%

Vehicle Cream

Eligibility Criteria

• Age: 9 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject must be at least 12 years of age. At selected site(s), a total of approximately eight subjects 9-11 years of age will be enrolled into the 2 arms of DFD-03 lotion group (active and vehicle).
• A clinical diagnosis of facial acne vulgaris with a facial Investigator's Global Assessment (IGA) score of 2 (mild) to 3 (moderate) at Baseline. At selected site(s), up to twelve subjects with acne lesions on the chest and/or back (including shoulders) in addition to those on the face will treat their chest and/or back (including shoulders) in addition to their face.
• Inflammatory lesion count (papules and pustules) of at least 20, non-inflammatory lesion count (closed and open comedones) of at least 25 on the face including the nose, and no more than 2 nodulocystic lesions. This criteria is not applicable to the 9-11 years age group as long as subjects have an IGA score of 2 (mild) to 3 (moderate) at Baseline.
• Females, regardless of childbearing potential: Must have a negative urine pregnancy test and if sexually active, must be on or use an acceptable method of birth control.
• Subjects agree not to use any product on the face during the entire course of study except for non-medicated, investigator-approved cleanser, sunscreen, face wash, and make-up as instructed by the investigator.
• Subjects must be willing to comply with sun avoidance measures for the face, including use of investigator-approved sunscreen and/or hats, have limited sun exposure time, and have no tanning bed use.
• Subject must be in good general health as determined by the investigator and supported by the medical history, physical examination and vital signs.

You may not qualify if:

• Females who are pregnant or lactating or planning to become pregnant during the study period.
• Treatment with the following products:
• Topical acne treatments or other topical facial medication in the 14 days prior to Baseline Systemic corticosteroids and systemic acne treatments in the 30 days prior to Baseline Systemic retinoid use in the 180 days prior to Baseline Undertaken certain facial procedures such as chemical peel, laser treatment, photodynamic therapy, acne surgery, cryodestruction or chemodestruction, x-ray therapy, intralesional steroids, dermabrasion, or depilation (except eyebrow shaping) in 30 days prior to Baseline.
• Treatment with a medication or procedure that, in the opinion of the investigator, would put the subject at unacceptable risk for participation in the study or may interfere with evaluations in the study.
• Treatment with an investigational product or device in 30 days prior to Baseline.
• Known allergic reaction to retinoids or tazarotene or any of the product ingredients.
• Presence of any facial skin disease or condition that would interfere with the study or place the subject at unacceptable risk including sunburn, rosacea, seborrheic dermatitis, perioral dermatitis, lupus, dermatomyositis, psoriasis, eczema, squamous cell carcinoma, acneiform eruptions caused by medications, steroid acne, steroid folliculitis, bacterial folliculitis or any other facial disease or condition.
• Subjects with a serious and or chronic medical condition such as chronic or active liver disease, renal impairment, heart disease, severe respiratory disease, rheumatoid arthritis, current malignancies, immunocompromised conditions, or any other disease that, in the opinion of the investigator, would interfere with the study or place the subject at unacceptable risk.
• Subjects who have been treated for alcohol dependence or alcohol or drug abuse in the year.

Sponsors & Collaborators

• Dr. Reddy's Laboratories Limited: lead

Study Sites (1)

International Dermatology Inc.

Miami, Florida, 33144, United States

Location

MeSH Terms

Conditions

Acne Vulgaris

Condition Hierarchy (Ancestors)

Acneiform Eruptions; Skin Diseases; Skin and Connective Tissue Diseases; Sebaceous Gland Diseases

Results Point of Contact

• Title: Dr. Srinivas Sidgiddi, Sr. Director, Clinical Development
• Organization: Dr. Reddy's Laboratories, Inc

srinivassidgiddi@drreddys.com

609-375-9910

Study Officials

• Srinivas R. Sidgiddi, M.D.

  Dr. Reddy's Laboratories Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 13, 2017
• First Posted: November 14, 2017
• Study Start: August 21, 2017
• Primary Completion: May 18, 2018
• Study Completion: May 18, 2018
• Last Updated: August 17, 2020
• Results First Posted: August 17, 2020

Record last verified: 2020-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)